Japanese cedar pollen allergy immunotherapy - ALK-Abello/Torii Pharmaceutical

Drug Profile

Japanese cedar pollen allergy immunotherapy - ALK-Abello/Torii Pharmaceutical

Alternative Names: CEDARCURE; immunotherapy sublingual tablet (SLIT-tablet) - ALK-Abello/Torii; TO-206

Latest Information Update: 28 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALK-Abello; Torii Pharmaceutical
  • Developer Torii Pharmaceutical
  • Class Allergens; Antiallergics; Japanese cedar pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Allergic rhinitis

Most Recent Events

  • 27 Sep 2017 Registered for Allergic rhinitis (In adults, In infants, In children, In adolescents) in Japan (Sublingual)
  • 25 Dec 2015 Preregistration for Allergic rhinitis in Japan (Sublingual)
  • 12 Nov 2015 Torii plans regulatory submission for Japanese cedar pollen allergy immunotherapy for Allergic rhinitis in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top